Literature DB >> 27087012

Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI.

Ijin Joo1,2, Jeong Min Lee3,4,5, Sang Min Lee1, Jeong Sub Lee1, Jin Young Park1, Joon Koo Han1,2,6.   

Abstract

PURPOSE: To investigate the utility of Liver Imaging Reporting and Data System (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas (IMCC) on gadoxetic acid-enhanced magnetic resonance imaging (MRI).
MATERIALS AND METHODS: This retrospective study was approved by our Institutional Review Board with waiver of informed consent. Pathologically confirmed IMCCs (n = 35) and hepatocellular carcinomas (HCCs) (n = 71) in patients with chronic hepatitis B or cirrhosis who had undergone gadoxetic acid-enhanced 3.0T or 1.5T MRI were included. Three radiologists independently assigned LI-RADS categories for each IMCC or HCC. Diagnostic performances of LR-M (probable malignancy, not specific for HCC) and LR-5/5v (definitely HCC) were investigated, and imaging features were compared between IMCCs of LR-M and non-LR-M.
RESULTS: In all, 88.6% (31/35), 80.0% (28/35), and 74.3% (26/35) of IMCCs and 12.7% (9/71), 22.5% (16/71), and 16.9% (12/71) of HCCs were assigned as LR-M by the three reviewers with substantial interobserver agreements (kappa = 0.664-0.741). Among IMCCs, 2.9% (1/35), 5.7% (2/35), and 11.4% (4/35) were categorized as LR-5/5v. IMCCs of non-LR-M (n = 8, using the consensus method) were significantly smaller (24.1 ± 17.4 vs. 62.8 ± 30.6 mm, P = 0.002) and showed higher frequencies of arterial hyperenhancement (75.0% (6/8) vs. 7.4% (2/27), P < 0.001) and lower frequencies of non-HCC malignancy-favoring features such as peripheral enhancement (12.5% (1/8) vs. 77.8% (21/27), P = 0.002) or the target appearance on the hepatobiliary phase (0% (0/8) vs. 81.5% (22/27), P < 0.001) than IMCCs of LR-M (n = 27).
CONCLUSION: Using LI-RADS, the majority of IMCCs can be accurately categorized as LR-M on gadoxetic acid-enhanced MRI; however, caution is warranted, as some atypical IMCCs may be assigned as LR-5/5v resulting in a false-positive diagnosis of HCC. J. Magn. Reson. Imaging 2016;44:1330-1338.
© 2016 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  LI-RADS; intrahepatic mass-forming cholangiocarcinoma; portal venous phase

Mesh:

Substances:

Year:  2016        PMID: 27087012     DOI: 10.1002/jmri.25287

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  21 in total

1.  Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging.

Authors:  Sun Kyung Jeon; Ijin Joo; Dong Ho Lee; Sang Min Lee; Hyo-Jin Kang; Kyoung-Bun Lee; Jeong Min Lee
Journal:  Eur Radiol       Date:  2018-06-28       Impact factor: 5.315

Review 2.  Emerging Role of the Pathologist in Precision Medicine for HCC.

Authors:  Thomas Longerich; Peter Schirmacher
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

Review 3.  Challenges in Diagnosis of Hepatocellular Carcinoma in Cirrhotic Liver: A Pathologist's Perspective.

Authors:  Dana Balitzer; Sanjay Kakar
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-05-01

4.  Performance of Gd-EOB-DTPA-enhanced MRI for the diagnosis of LI-RADS 4 category hepatocellular carcinoma nodules with different diameters.

Authors:  Qi Tang; Cong Ma
Journal:  Oncol Lett       Date:  2018-06-04       Impact factor: 2.967

5.  Comparison between M-score and LR-M in the reporting system of contrast-enhanced ultrasound LI-RADS.

Authors:  Li-Da Chen; Si-Min Ruan; Yuan Lin; Jin-Yu Liang; Shun-Li Shen; Hang-Tong Hu; Yang Huang; Wei Li; Zhu Wang; Xiao-Yan Xie; Ming-De Lu; Ming Kuang; Wei Wang
Journal:  Eur Radiol       Date:  2018-12-19       Impact factor: 5.315

Review 6.  Pitfalls and problems to be solved in the diagnostic CT/MRI Liver Imaging Reporting and Data System (LI-RADS).

Authors:  Yeun-Yoon Kim; Jin-Young Choi; Claude B Sirlin; Chansik An; Myeong-Jin Kim
Journal:  Eur Radiol       Date:  2018-08-16       Impact factor: 5.315

7.  Capsule, septum, and T2 hyperintense foci for differentiation between large hepatocellular carcinoma (≥5 cm) and intrahepatic cholangiocarcinoma on gadoxetic acid MRI.

Authors:  Jiyoung Hwang; Young Kon Kim; Ji Hye Min; Seo-Youn Choi; Woo Kyung Jeong; Seong Sook Hong; Hyun-Joo Kim; Soohyun Ahn; Hyeon Seon Ahn
Journal:  Eur Radiol       Date:  2017-05-12       Impact factor: 5.315

8.  Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.

Authors:  Yeun-Yoon Kim; Chansik An; Sungwon Kim; Myeong-Jin Kim
Journal:  Eur Radiol       Date:  2017-12-11       Impact factor: 5.315

9.  Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018.

Authors:  Daniel R Ludwig; Tyler J Fraum; Roberto Cannella; David H Ballard; Richard Tsai; Muhammad Naeem; Maverick LeBlanc; Amber Salter; Allan Tsung; Anup S Shetty; Amir A Borhani; Alessandro Furlan; Kathryn J Fowler
Journal:  Abdom Radiol (NY)       Date:  2019-06

10.  Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging.

Authors:  Seo-Youn Choi; Young Kon Kim; Ji Hye Min; Tae Wook Kang; Woo Kyoung Jeong; Soohyun Ahn; Hojeong Won
Journal:  Eur Radiol       Date:  2018-01-15       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.